Skip to main content
OpenTrials
Completed

NCT Number: NCT00688077

FGF-23 Suppressibility by Calcitonin

Introduction:

Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of FGF-23 production and secretion in healthy humans.

Aim:

In this study we wish to examine the FGF-23 suppressive effects of calcitonin in healthy men.

Study Design:

placebo-controlled, cross-over study

Method:

* All twelve subjects are examined on two occasions, once after exposure to placebo 1 ml NaCl 0.9% subcutaneously, and once following calcitonin 200 IU/ml subcutaneously * On both occasions frequent bloodsampling will take place, out an indwelling catheter in de forearm vein. * Sampling times: -15, 0, 60, 120, 240, 360, and 480 minutes * Mealtimes: Calcium and Phosphate intake standardized on both occasions * All samples are analyzed for FGF-23, using a C-terminal FGF-23 ELISA kit (Immunotopics, San Clemente, USA) that measures intact and C-terminal fragments of FGF-23, and one that measures only intact FGF-23 * Samples obtained at T-15, T0, T240 and T480 are stored for later analysis of Ca, albumin, PO4, PTH, 25-OHD and 1,25-OHD

Endpoint:

A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Rijnstate Hospital

Arnhem, Gelderland, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy man, who are between 20-55 years old, and have a BMI 20-27 kg/m2.

Exclusion criteria

  • Serum creatinin >100 mmol/L, or glomerular filtration rate <80 ml/min.
  • Abnormal serum Ca, PO4, albumin, 25-OH vitamin D, or PTH levels.
  • Any medication.

Treatment and study plan

Calcitonin

Drug

Calcitonin 200 IU/ml, single subcutaneous injection, experimental group

Placebo

Drug

NaCl 0,9 % 1ml, single subcutaneous injection, placebo group

Primary outcomes

  1. A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.

    Time frame: eight hours

Sponsors and collaborators

Lead sponsor

Rijnstate Hospital

Other

Registry information

Official study title

Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study

Important dates

Study start
2008
Primary completion
2012
First posted
Jun 2, 2008
Registry last updated
Jun 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.